Curcumin loaded NLC induces histone hypoacetylation in the CNS after intraperitoneal administration in mice

Puglia, Carmelo; Frasca, Giampiero; Musumeci, Teresa; Rizza, Luisa; Puglisi, Giovanni; Bonina, Francesco; Chiechio, Santina

doi:10.1016/j.ejpb.2012.03.015

Cited by 68 publications

(48 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…29 It is supported by the high EE when ATO 5 is used to incorporate the lipophilic drug Itraconazole into lipid NPs. 34 The high EE may also be attributed to the massive crystal order disturbance caused by the incorporation of liquid lipid in solid lipid, resulting in a lipid matrix with crystal lattice defects, which provides enough space to accommodate drug molecules in the matrix.…”

Section: Physical Characterization Of Dox/ Cur-npsmentioning

confidence: 94%

“…Lipid NPs have been demonstrated to successfully deliver DOX 26,27 or Cur 28,29 individually in previous studies due to good biocompatibility, high encapsulation efficacy (EE), sustained drug release, excellent stability, passive targeted delivery of anticancer drugs, and enhanced anticancer activity. We have successfully developed lipid NPs to deliver triptolide 30 and podophyllotoxin 31 in our previous studies.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Codelivery of doxorubicin and curcumin with lipid nanoparticles results in improved efficacy of chemotherapy in liver cancer

Zhao¹,

Chen²,

Liu³

et al. 2014

IJN

View full text Add to dashboard Cite

Liver cancer is a leading cause of cancer deaths worldwide. The combination therapy of cytotoxic and chemosensitizing agents loaded in nanoparticles has been highlighted as an effective treatment for different cancers. However, such studies in liver cancer remain very limited. In our study, we aim to develop a novel lipid nanoparticles loaded with doxorubicin (DOX) (an effective drug for liver cancer) and curcumin (Cur) (a chemosensitizer) simultaneously, and we examined the efficacy of chemotherapy in liver cancer. DOX and Cur codelivery lipid nanoparticles (DOX/Cur-NPs) were successfully prepared using a high-pressure microfluidics technique, showing a mean particle size of around 90 nm, a polydispersity index <0.3, and a zeta potential <−10 mV. The encapsulation efficacy was >90% for both DOX and Cur. The blank lipid nanoparticles were nontoxic, as determined by a cell cytotoxicity study in human normal liver cells L02 and liver cancer cells HepG2. In vitro DOX release studies revealed a sustained-release pattern until 48 hours in DOX/Cur-NPs. We found enhanced cytotoxicity and decreased inhibitory concentration (IC) 50 in HepG2 cells and reduced cytotoxicity in L02 cells treated with DOX/Cur-NPs, suggesting the synergistic effects of DOX/Cur-NPs compared with free DOX and DOX nanoparticles (NPs). The optimal weight ratio of DOX and Cur was 1:1. Annexin-V-fluorescein isothiocyanate/propidium iodide double staining showed enhanced apoptosis in HepG2 cells treated with DOX/Cur-NPs compared with free DOX and DOX-NPs. An in vivo experiment showed the synergistic effect of DOX/Cur-NPs compared with DOX-NPs on liver tumor growth inhibition. Taken together, the simultaneous delivery of DOX and Cur by DOX/Cur-NPs might be a promising treatment for liver cancer.

show abstract

Section: Physical Characterization Of Dox/ Cur-npsmentioning

confidence: 94%

Section: Introductionmentioning

confidence: 99%

Codelivery of doxorubicin and curcumin with lipid nanoparticles results in improved efficacy of chemotherapy in liver cancer

Zhao¹,

Chen²,

Liu³

et al. 2014

IJN

View full text Add to dashboard Cite

show abstract

“…SLNs and liposomes can be helpful in this regard 19 23 . On the other hand, reports on the use of modified SLNs as a carrier of curcumin are scarce 24 . Hence, the long-term stability of curcumin loaded into modified SLNs and its release are interesting topics of research 21 .…”

Section: Selection Of An Appropriate Blend Of Lipids Is Key Tomentioning

confidence: 99%

“…SLNs were prepared using the standard method of hot homogenization followed by ultrasonication 14,24 . Further details are available in our recent publications 14,15 .…”

Section: Preparation Of Slnsmentioning

confidence: 99%

Effects of Fatty Acids on the Interfacial and Solution Behavior of Mixed Lipidic Aggregates Called Solid Lipid Nanoparticles

et al. 2016

View full text Add to dashboard Cite

“…Approximately 100 mg/kg of a histone acetyltransferase inhibitor II (HAT inhibitor, Merck, Darmstadt, Germany) in 1% DMSO [12] was injected intraperitoneally into the mice throughout the experimental period (injection every other day for 20 days), while 1% DMSO was injected into the control mice. In addition, as a judgment result of the atopic score of the dorsal skin by the dosises 1, 5 and 10µg/mouse of acetyl-β-End, we used the smallest dose (5µg/mouse) that showed the significant amelioration effect (Data not shown).…”

Section: Hat Inhibitor Treatmentmentioning

confidence: 99%

Dariers disease and pregnancy

Quinlivan¹,

O'Halloran²

2013

Dermatol Aspects

View full text Add to dashboard Cite

Background: Atopic dermatitis (AD) is known to be affected by neuropeptides. However, the mechanism underlying this phenomenon is unclear. This study analyzed the mechanism(s) responsible for the influence of β-endorphin (β-End) or N-acetyl-β-endorphin (acetyl-β-End) on AD. Methods: Specific pathogen-free (SPF) and conventional NC/Nga mice were used for the studies. Conventional (not SPF) mice, spontaneously develop dermal symptoms similar to that of patients with AD. In the present study we treated mice with 5 µg/mouse of β-End or acetyl-β-End for 20 days. In addition, a histone acetyltransferase inhibitor II (HAT inhibitor, 100 mg/kg) was given for 20 days to examine its effects on the acetylation of the β-End. Results: The symptoms of the conventional group were ameliorated by both β-End and acetyl-β-End treatment, although acetyl-β-End treatment more effectively relieved the symptoms than β-End, and the improvement induced by the β-End treatment disappeared following HAT inhibitor treatment. Conclusions: These observations suggested that β-End or acetyl-β-End treatment can suppress the symptoms of AD in the mice, and that the effect of the β-End is induced by the acetylation of the β-End by HAT.

show abstract

Curcumin loaded NLC induces histone hypoacetylation in the CNS after intraperitoneal administration in mice

Cited by 68 publications

References 36 publications

Codelivery of doxorubicin and curcumin with lipid nanoparticles results in improved efficacy of chemotherapy in liver cancer

Codelivery of doxorubicin and curcumin with lipid nanoparticles results in improved efficacy of chemotherapy in liver cancer

Effects of Fatty Acids on the Interfacial and Solution Behavior of Mixed Lipidic Aggregates Called Solid Lipid Nanoparticles

Dariers disease and pregnancy

Contact Info

Product

Resources

About

Curcumin loaded NLC induces histone hypoacetylation in the CNS after intraperitoneal administration in mice

Cited by 68 publications

References 36 publications

Codelivery of doxorubicin and curcumin with&nbsp;lipid nanoparticles results in improved efficacy of&nbsp;chemotherapy in liver cancer

Codelivery of doxorubicin and curcumin with&nbsp;lipid nanoparticles results in improved efficacy of&nbsp;chemotherapy in liver cancer

Effects of Fatty Acids on the Interfacial and Solution Behavior of Mixed Lipidic Aggregates Called Solid Lipid Nanoparticles

Dariers disease and pregnancy

Contact Info

Product

Resources

About

Codelivery of doxorubicin and curcumin with lipid nanoparticles results in improved efficacy of chemotherapy in liver cancer

Codelivery of doxorubicin and curcumin with lipid nanoparticles results in improved efficacy of chemotherapy in liver cancer